Journal of Stroke & Cerebrovascular Diseases
Volume 18, Issue 5 , Pages 381-383 , September 2009

Sildenafil Treatment of Subacute Ischemic Stroke: A Safety Study at 25-mg Daily for 2 Weeks

  • Brian Silver, MD

      Affiliations

    • Department of Neurology, Henry Ford Hospital, Detroit, Michigan
    • Corresponding Author InformationAddress correspondence to Brian Silver, MD, Department of Neurology, Henry Ford Hospital, 2799 W Grand Blvd, K-11, Detroit, MI 48202.
    • ,
  • Sharon McCarthy, RN

      Affiliations

    • Department of Neurology, Henry Ford Hospital, Detroit, Michigan
    • ,
  • Mei Lu, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, Henry Ford Hospital, Detroit, Michigan
    • ,
  • Panayiotis Mitsias, MD

      Affiliations

    • Department of Neurology, Henry Ford Hospital, Detroit, Michigan
    • ,
  • Andrew N. Russman, DO

      Affiliations

    • Department of Neurology, Henry Ford Hospital, Detroit, Michigan
    • ,
  • Angelos Katramados, MD

      Affiliations

    • Department of Neurology, Henry Ford Hospital, Detroit, Michigan
    • ,
  • Daniel C. Morris, MD

      Affiliations

    • Department of Emergency Medicine, Henry Ford Hospital, Detroit, Michigan
    • ,
  • Christopher A. Lewandowski, MD

      Affiliations

    • Department of Emergency Medicine, Henry Ford Hospital, Detroit, Michigan
    • ,
  • Michael Chopp, PhD

      Affiliations

    • Department of Neurology, Henry Ford Hospital, Detroit, Michigan

Received 10 October 2008 ,Revised 25 December 2008 ,Accepted 6 January 2009.

References 

  1. Zhang R, Wang Y, Zhang L, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke. 2002;33:2675–2680
  2. Zhang R, Wang L, Zhang L, et al. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ Res. 2003;92:308–313
  3. Zhang L, Zhang RL, Wang Y, et al. Functional recovery in aged and young rats after embolic stroke: Treatment with a phosphodiesterase type 5 inhibitor. Stroke. 2005;36:847–852
  4. Wang L, Gang Zhang Z, Lan Zhang R, et al. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J Cereb Blood Flow Metab. 2005;25:1150–1158
  5. Zhang RL, Zhang Z, Zhang L, et al. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res. 2006;83:1213–1219
  6. Li L, Jiang Q, Zhang L, et al. Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res. 2007;1132:185–192
  7. Zhang L, Zhang Z, Zhang RL, et al. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res. 2006;1118:192–198
  8. Silver B, Grover KM, Arcila X, et al. Recovery in a patient with locked-in syndrome. Can J Neurol Sci. 2006;33:246–249
  9. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587
  10. Sherman DG, Albers GW, Bladin C, et al. PREVAIL Investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischemic stroke (PREVAIL study): An open-label randomized comparison. Lancet. 2007;369:1347–1355
  11. Viagra (sildenafil citrate) Information. US Food and Drug Administration. Viagra (sildenafil citrate) Information. Available from: http://www.fda.gov/cder/consumerinfo/viagra/default.htm. Accessed April 7, 2008.
  12. Paul GA, Gibbs JSR, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005;60:107–112
  13. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53:5S–12S(suppl)
  14. Muirhead GJ, Rance DJ, Walker DK, et al. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br J Clin Pharmacol. 2002;53:13S–20S(suppl)
  15. Edwards G, Muirhead G. Introduction to the pharmacokinetics and pharmacodynamics of sildenafil citrate. Br J Clin Pharmacol. 2002;53:1S–3S(suppl)

 Supported by the Harris Family Philanthropic Fund. Drs. Chopp, Lu, Mitsias, and Silver were supported by a National Institutes of Health Stroke Center program project grant number NS-23393.

PII: S1052-3057(09)00022-6

doi: 10.1016/j.jstrokecerebrovasdis.2009.01.007

Journal of Stroke & Cerebrovascular Diseases
Volume 18, Issue 5 , Pages 381-383 , September 2009

Article Tools

* Image Usage & Resolution